---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-088054"
form_type: "8-K"
ticker: "HRGN"
cik: "0001563665"
company_name: "Harvard Apparatus Regenerative Technology, Inc."
filed_at: "2022-08-10T23:59:59+00:00"
generated_at: "2026-06-24T01:24:37.259380+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Biostage appoints Joseph Damasio as CFO; $250K salary, 116K-share option grant

## Summary
- Mr. Damasio appointed CFO effective August 8, 2022; brings capital raising and biotech finance experience.
- Initial annual base salary of $250,000, plus $25,000 bonus for remainder of FY2022 subject to milestones.
- Granted nonqualified stock option for 116,156 shares vesting equally over four years.
- Company intends to relist on NASDAQ and start clinical trial for esophageal implant.
- Interim CEO David Green highlights Damasio's skills for operational management and capital raises.

## SEC filing metadata
- accession: 0001104659-22-088054
- form_type: 8-K
- ticker: HRGN
- cik: 0001563665
- company_name: Harvard Apparatus Regenerative Technology, Inc.
- filed_at: 2022-08-10T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563665/000110465922088054/0001104659-22-088054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563665/000110465922088054/tm2222955d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-088054
- JSON: https://secwatch.observer/filing/0001104659-22-088054.json
- Plain text: https://secwatch.observer/filing/0001104659-22-088054.txt

## Key facts
- Executive change
  Joseph L. Damasio, Jr. was appointed as Chief Financial Officer at Harvard Apparatus Regenerative Technology, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: Effective as of August 8, 2022, Biostage, Inc. (the Company) appointed Joseph L. Damasio, Jr., as Chief Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1563665/000110465922088054/0001104659-22-088054-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.